Research graph
References from Stepwise Increase in Concentrations of Atropine Treatment for Myopia Control Study. Local targets link to admitted publications; unresolved targets remain external evidence.
Myopia
10.1038/s41572-020-00231-4 · 2020 · External reference
Epidemiology of myopia
10.1097/apo.0000000000000236 · 2016 · External reference
Refractive errors in university students in central China: the Anyang University Students Eye Study
10.1167/iovs.18-24363 · 2018 · External reference
Myopia and associated pathological complications
10.1111/j.1475-1313.2005.00298.x · 2005 · External reference
Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review
10.1016/j.ajo.2013.08.010 · 2014 · External reference
IMI impact of myopia
10.1167/iovs.62.5.2 · 2021 · External reference
Direct costs of myopia in Singapore
10.1038/eye.2008.225 · 2009 · External reference
Atropine for the treatment of childhood myopia
10.1016/j.ophtha.2006.05.062 · 2006 · External reference
Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (atropine for the Treatment of Myopia 2)
10.1016/j.ophtha.2011.07.031 · 2012 · External reference
Prevention of myopia progression with 0.05% atropine solution
10.1089/jop.2006.22.41 · 2006 · External reference
The long-term results of using low-concentration atropine eye drops for controlling myopia progression in schoolchildren
10.1089/jop.2011.0027 · 2011 · External reference
Atropine 0.01% eyedrops significantly reduce the progression of childhood myopia
10.1089/jop.2015.0043 · 2015 · External reference
Low-Concentration atropine for myopia progression (LAMP) Study: a randomized, Double-Blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control
10.1016/j.ophtha.2018.05.029 · 2019 · External reference
Two-Year clinical trial of the low-concentration atropine for myopia progression (LAMP) Study: phase 2 report
10.1016/j.ophtha.2019.12.011 · 2019 · External reference
Low-dose (0.01%) atropine eye-drops to reduce progression of myopia in children: a multicentre placebo-controlled randomised trial in the UK (CHAMP-UK)-study protocol
10.1136/bjophthalmol-2019-314819 · 2019 · External reference
Low-concentration atropine eyedrops for myopia control in a multi-racial cohort of Australian children: a randomised clinical trial
10.1111/ceo.14148 · 2022 · External reference
Atropine for the treatment of childhood myopia in India: multicentric randomized trial
10.1016/j.ophtha.2021.01.026 · 2021 · External reference
Atropine slows myopia progression more in Asian than white children by meta-analysis
10.1097/opx.0000000000000178 · 2014 · External reference
Effect of low-dose atropine on myopia progression, pupil diameter and accommodative amplitude: low-dose atropine and myopia progression
2020 · External reference
Interventions for myopia control in children: a living systematic review and network meta-analysis
2025 · External reference
IMI-Interventions for controlling myopia onset and progression 2025
10.1167/iovs.66.12.39 · 2025 · External reference
Efficacy and safety of consecutive use of 1% and 0.01% atropine for myopia control in Chinese children: the Atropine for Children and Adolescent Myopia Progression Study
10.1007/s40123-022-00572-1 · 2022 · External reference
Safety and efficacy of low-dose atropine eyedrops for the treatment of myopia progression in Chinese children: a randomized clinical trial
10.1001/jamaophthalmol.2020.3820 · 2020 · External reference
Myopia progression after cessation of low-dose atropine eyedrops treatment: a two-year randomized, double-masked, placebo-controlled, cross-over trial
10.1111/aos.15235 · 2023 · External reference
Risk factors for progressive myopia in the atropine therapy for myopia study
10.1016/j.ajo.2015.01.029 · 2015 · External reference
Age Effect on Treatment Responses to 0.05%, 0.025%, and 0.01% atropine: Low-Concentration atropine for Myopia Progression Study
10.1016/j.ophtha.2020.12.036 · 2021 · External reference
The Association of choroidal thickening by atropine with treatment effects for myopia: two-year clinical trial of the low-concentration atropine for myopia progression (LAMP) Study
10.1016/j.ajo.2021.12.014 · 2022 · External reference
Analysis of factors that may affect the effect of atropine 0.01% on myopia control
2020 · External reference
Update in myopia and treatment strategy of atropine use in myopia control
10.1038/s41433-018-0139-7 · 2019 · External reference
Stepwise low concentration atropine for myopic control: a 10-year cohort study
10.1038/s41598-021-96698-6 · 2021 · External reference
Annual incidences and progressions of myopia and high myopia in Chinese schoolchildren based on a 5-Year cohort Study
10.1167/iovs.63.1.8 · 2022 · External reference
Regression to the mean: what it is and how to deal with it
10.1093/ije/dyh299 · 2005 · External reference
Pediatric eye disease investigator group. Does past myopia progression predict future progression?
10.1167/iovs.67.1.38 · 2026 · External reference
The limited value of prior change in predicting future progression of juvenile-onset myopia
10.1097/opx.0000000000001883 · 2022 · External reference
Safety and efficacy of low-dose atropine eyedrops for the treatment of myopia progression in Chinese children: a randomized clinical trial
10.1001/jamaophthalmol.2020.3820 · ExternalCitation · doi-reference
Efficacy and safety of consecutive use of 1% and 0.01% atropine for myopia control in Chinese children: the Atropine for Children and Adolescent Myopia Progression Study
10.1007/s40123-022-00572-1 · ExternalCitation · doi-reference
Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review
10.1016/j.ajo.2013.08.010 · ExternalCitation · doi-reference
Risk factors for progressive myopia in the atropine therapy for myopia study
10.1016/j.ajo.2015.01.029 · ExternalCitation · doi-reference
The Association of choroidal thickening by atropine with treatment effects for myopia: two-year clinical trial of the low-concentration atropine for myopia progression (LAMP) Study
10.1016/j.ajo.2021.12.014 · ExternalCitation · doi-reference
Atropine for the treatment of childhood myopia
10.1016/j.ophtha.2006.05.062 · ExternalCitation · doi-reference
Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (atropine for the Treatment of Myopia 2)
10.1016/j.ophtha.2011.07.031 · ExternalCitation · doi-reference
Low-Concentration atropine for myopia progression (LAMP) Study: a randomized, Double-Blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control
10.1016/j.ophtha.2018.05.029 · ExternalCitation · doi-reference
Two-Year clinical trial of the low-concentration atropine for myopia progression (LAMP) Study: phase 2 report
10.1016/j.ophtha.2019.12.011 · ExternalCitation · doi-reference
Age Effect on Treatment Responses to 0.05%, 0.025%, and 0.01% atropine: Low-Concentration atropine for Myopia Progression Study
10.1016/j.ophtha.2020.12.036 · ExternalCitation · doi-reference
Atropine for the treatment of childhood myopia in India: multicentric randomized trial
10.1016/j.ophtha.2021.01.026 · ExternalCitation · doi-reference
Direct costs of myopia in Singapore
10.1038/eye.2008.225 · ExternalCitation · doi-reference
Update in myopia and treatment strategy of atropine use in myopia control
10.1038/s41433-018-0139-7 · ExternalCitation · doi-reference
Myopia
10.1038/s41572-020-00231-4 · ExternalCitation · doi-reference
Stepwise low concentration atropine for myopic control: a 10-year cohort study
10.1038/s41598-021-96698-6 · ExternalCitation · doi-reference
Prevention of myopia progression with 0.05% atropine solution
10.1089/jop.2006.22.41 · ExternalCitation · doi-reference
The long-term results of using low-concentration atropine eye drops for controlling myopia progression in schoolchildren
10.1089/jop.2011.0027 · ExternalCitation · doi-reference
Atropine 0.01% eyedrops significantly reduce the progression of childhood myopia
10.1089/jop.2015.0043 · ExternalCitation · doi-reference
Regression to the mean: what it is and how to deal with it
10.1093/ije/dyh299 · ExternalCitation · doi-reference
Epidemiology of myopia
10.1097/apo.0000000000000236 · ExternalCitation · doi-reference
Atropine slows myopia progression more in Asian than white children by meta-analysis
10.1097/opx.0000000000000178 · ExternalCitation · doi-reference
The limited value of prior change in predicting future progression of juvenile-onset myopia
10.1097/opx.0000000000001883 · ExternalCitation · doi-reference
Myopia progression after cessation of low-dose atropine eyedrops treatment: a two-year randomized, double-masked, placebo-controlled, cross-over trial
10.1111/aos.15235 · ExternalCitation · doi-reference
Low-concentration atropine eyedrops for myopia control in a multi-racial cohort of Australian children: a randomised clinical trial
10.1111/ceo.14148 · ExternalCitation · doi-reference
Myopia and associated pathological complications
10.1111/j.1475-1313.2005.00298.x · ExternalCitation · doi-reference
Low-dose (0.01%) atropine eye-drops to reduce progression of myopia in children: a multicentre placebo-controlled randomised trial in the UK (CHAMP-UK)-study protocol
10.1136/bjophthalmol-2019-314819 · ExternalCitation · doi-reference
Refractive errors in university students in central China: the Anyang University Students Eye Study
10.1167/iovs.18-24363 · ExternalCitation · doi-reference
IMI impact of myopia
10.1167/iovs.62.5.2 · ExternalCitation · doi-reference
Annual incidences and progressions of myopia and high myopia in Chinese schoolchildren based on a 5-Year cohort Study
10.1167/iovs.63.1.8 · ExternalCitation · doi-reference
IMI-Interventions for controlling myopia onset and progression 2025
10.1167/iovs.66.12.39 · ExternalCitation · doi-reference
Pediatric eye disease investigator group. Does past myopia progression predict future progression?
10.1167/iovs.67.1.38 · ExternalCitation · doi-reference
